银屑病和银屑病关节炎患者生物药物生存期的可选生物制剂和疾病组影响

IF 1.5 4区医学 Q3 DERMATOLOGY Annals of Dermatology Pub Date : 2022-10-01 DOI:10.5021/ad.22.003

Sohee Oh, Sungjun Choi, Hyun-Sun Yoon

{"title":"银屑病和银屑病关节炎患者生物药物生存期的可选生物制剂和疾病组影响","authors":"Sohee Oh, Sungjun Choi, Hyun-Sun Yoon","doi":"10.5021/ad.22.003","DOIUrl":null,"url":null,"abstract":"Background: Factors other than efficacy and safety could influence the survival of biologics in patients with psoriasis. Little is known about whether different disease groups affect drug survival of biologics or not.Objective: This study aimed to investigate whether the availability of alternative biologics and disease groups could influence drug survival of biologics approved for psoriasis and psoriasis arthritis (PsA).Methods: A nationwide population-based retrospective cohort study was conducted using the Health Insurance and Review Assessment data in Korea between January 2009 and August 2019.Results: The drug survival analysis included 5,634 biologic episodes. Ustekinumab was the most frequently prescribed drug (n=2,488, 44.2%). Multivariable time-dependent Cox regression analysis showed that higher age, female sex, no comorbidity, concomitant cyclosporine or acitretin use, biologic-experienced and use of tumor necrosis factor (TNF)-α inhibitors were predictors of drug discontinuation. PsA was a predictor of drug persistence, particularly for TNF-α inhibitors. Ustekinumab and adalimumab discontinuation significantly increased after introducing secukinumab and ustekinumab, respectively.Conclusion: The availability of alternative biologics and disease groups affect biologic drug survival in patients with psoriasis and PsA.","PeriodicalId":8233,"journal":{"name":"Annals of Dermatology","volume":"34 5","pages":"321-330"},"PeriodicalIF":1.5000,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/2f/b4/ad-34-321.PMC9561298.pdf","citationCount":"2","resultStr":"{\"title\":\"Available Alternative Biologics and Disease Groups Influence Biologic Drug Survival in Patients with Psoriasis and Psoriatic Arthritis.\",\"authors\":\"Sohee Oh, Sungjun Choi, Hyun-Sun Yoon\",\"doi\":\"10.5021/ad.22.003\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Factors other than efficacy and safety could influence the survival of biologics in patients with psoriasis. Little is known about whether different disease groups affect drug survival of biologics or not.Objective: This study aimed to investigate whether the availability of alternative biologics and disease groups could influence drug survival of biologics approved for psoriasis and psoriasis arthritis (PsA).Methods: A nationwide population-based retrospective cohort study was conducted using the Health Insurance and Review Assessment data in Korea between January 2009 and August 2019.Results: The drug survival analysis included 5,634 biologic episodes. Ustekinumab was the most frequently prescribed drug (n=2,488, 44.2%). Multivariable time-dependent Cox regression analysis showed that higher age, female sex, no comorbidity, concomitant cyclosporine or acitretin use, biologic-experienced and use of tumor necrosis factor (TNF)-α inhibitors were predictors of drug discontinuation. PsA was a predictor of drug persistence, particularly for TNF-α inhibitors. Ustekinumab and adalimumab discontinuation significantly increased after introducing secukinumab and ustekinumab, respectively.Conclusion: The availability of alternative biologics and disease groups affect biologic drug survival in patients with psoriasis and PsA.\",\"PeriodicalId\":8233,\"journal\":{\"name\":\"Annals of Dermatology\",\"volume\":\"34 5\",\"pages\":\"321-330\"},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2022-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/2f/b4/ad-34-321.PMC9561298.pdf\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annals of Dermatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.5021/ad.22.003\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Dermatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5021/ad.22.003","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 2

摘要

背景:除疗效和安全性外，其他因素可能影响生物制剂在银屑病患者中的生存。不同的疾病群体是否会影响生物制剂的药物生存期尚不清楚。目的:本研究旨在探讨替代生物制剂和疾病组的可用性是否会影响已批准用于银屑病和银屑病关节炎(PsA)的生物制剂的药物生存期。方法:利用韩国2009年1月至2019年8月的健康保险和审查评估数据进行了一项基于全国人群的回顾性队列研究。结果:药物生存期分析包括5634次生物学发作。Ustekinumab是最常用的处方药(n= 2488, 44.2%)。多变量时间相关Cox回归分析显示，年龄较大、女性、无合并症、同时使用环孢素或阿维素、生物经验和使用肿瘤坏死因子(TNF)-α抑制剂是停药的预测因素。PsA是药物持久性的预测因子，尤其是TNF-α抑制剂。在引入secukinumab和Ustekinumab后，Ustekinumab和阿达木单抗的停药率分别显著增加。结论:替代生物制剂的可及性和疾病组影响银屑病和PsA患者的生物药物生存。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

摘要图片

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Available Alternative Biologics and Disease Groups Influence Biologic Drug Survival in Patients with Psoriasis and Psoriatic Arthritis.

Background: Factors other than efficacy and safety could influence the survival of biologics in patients with psoriasis. Little is known about whether different disease groups affect drug survival of biologics or not.

Objective: This study aimed to investigate whether the availability of alternative biologics and disease groups could influence drug survival of biologics approved for psoriasis and psoriasis arthritis (PsA).

Methods: A nationwide population-based retrospective cohort study was conducted using the Health Insurance and Review Assessment data in Korea between January 2009 and August 2019.

Results: The drug survival analysis included 5,634 biologic episodes. Ustekinumab was the most frequently prescribed drug (n=2,488, 44.2%). Multivariable time-dependent Cox regression analysis showed that higher age, female sex, no comorbidity, concomitant cyclosporine or acitretin use, biologic-experienced and use of tumor necrosis factor (TNF)-α inhibitors were predictors of drug discontinuation. PsA was a predictor of drug persistence, particularly for TNF-α inhibitors. Ustekinumab and adalimumab discontinuation significantly increased after introducing secukinumab and ustekinumab, respectively.

Conclusion: The availability of alternative biologics and disease groups affect biologic drug survival in patients with psoriasis and PsA.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Annals of Dermatology 医学-皮肤病学

CiteScore

1.60

自引率

6.20%

发文量

审稿时长

6-12 weeks

期刊介绍： Annals of Dermatology (Ann Dermatol) is the official peer-reviewed publication of the Korean Dermatological Association and the Korean Society for Investigative Dermatology. Since 1989, Ann Dermatol has contributed as a platform for communicating the latest research outcome and recent trend of dermatology in Korea and all over the world. Ann Dermatol seeks for ameliorated understanding of skin and skin-related disease for clinicians and researchers. Ann Dermatol deals with diverse skin-related topics from laboratory investigations to clinical outcomes and invites review articles, original articles, case reports, brief reports and items of correspondence. Ann Dermatol is interested in contributions from all countries in which good and advanced research is carried out. Ann Dermatol willingly recruits well-organized and significant manuscripts with proper scope throughout the world.